0001193125-23-249487.txt : 20231003 0001193125-23-249487.hdr.sgml : 20231003 20231003071928 ACCESSION NUMBER: 0001193125-23-249487 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20231003 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231003 DATE AS OF CHANGE: 20231003 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intellia Therapeutics, Inc. CENTRAL INDEX KEY: 0001652130 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 364785571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37766 FILM NUMBER: 231301550 BUSINESS ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-285-6200 MAIL ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 d556975d8k.htm 8-K 8-K
false 0001652130 0001652130 2023-10-03 2023-10-03

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 3, 2023

 

 

INTELLIA THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-37766   36-4785571

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

40 Erie Street, Suite 130

Cambridge, Massachusetts

   02139
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (857) 285-6200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   NTLA   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01.

Regulation FD Disclosure.

On October 3, 2023, Intellia Therapeutics, Inc. (“Intellia”) issued a press release titled “Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished herewith and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 8.01.

Other Events.

On October 3, 2023, Regeneron Pharmaceuticals, Inc. (“Regeneron”) and Intellia announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases. This expansion builds on the success of the companies’ existing collaboration and continues to combine both companies’ deep biology and technology expertise. The collaboration will leverage Regeneron’s proprietary antibody-targeted adeno-associated virus (AAV) vectors and delivery systems and Intellia’s proprietary Nme2 CRISPR/Cas9 systems adapted for viral vector delivery and designed to precisely modify a target gene.

Under the terms of the expanded agreement, the companies will initially research two in vivo non-liver targets. Intellia will lead the design of the editing methodology and Regeneron will lead the design of the targeted viral vector delivery approach. Each company will have the opportunity to lead potential development and commercialization of product candidates for one target, and the company that is not leading development and commercialization will have the option to enter into a co-development and co-commercialization agreement for the target.

Forward Looking Statements.

This Current Report on Form 8-K and certain of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations regarding: its strategy, business plans and focus; its ability to quickly and efficiently realize the scope and potential of its genome editing technology; its ability to maintain, expand and maximize its intellectual property portfolio and pipeline as well as accelerate clinical validation for its platform, including through its existing and expanded collaboration with Regeneron; the therapeutic value and development potential of CRISPR/Cas9 genome editing technologies and therapies; Intellia’s ability to combine its CRISPR genome editing platform with Regeneron’s proprietary AAV vectors and delivery systems; and the expected strategic benefits of any current or future collaborations.

Any forward-looking statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that could cause actual results to differ materially and adversely from those set forth in or implied by any forward-looking statements. These risks, uncertainties and factors include, but are not limited to: risks related to Intellia’s relationship with third parties, including its licensors and licensees; risks related to the ability of Intellia’s licensors to protect and maintain their intellectual property position; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for the new company’s product candidates; the risk that any one or more of the collaboration product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and the risk that Intellia’s collaboration with Regeneron or its other collaborations will not continue or will not be successful.. For a discussion of these and other risks, uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”), as well as discussions of potential risks, uncertainties and other important factors in Intellia’s other filings with the SEC, including those contained or incorporated by reference. Any forward-looking statements represent Intellia’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Intellia explicitly disclaims any obligation to update any forward-looking statements, except as required by law.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.		   

Description

99.1    Press Release, dated October 3, 2023.
104    104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 3, 2023

   Intellia Therapeutics, Inc.
    By:  

/s/ John M. Leonard

    Name:   John M. Leonard
    Title:   Chief Executive Officer and President
 EX-99.1 2 d556975dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO       LOGO

 

LOGO

Regeneron and Intellia Announce Expanded Research Collaboration

to Develop CRISPR-Based Therapies for the Treatment of

Neurological and Muscular Diseases

 

  •  

Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases

TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 3, 2023 – Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases. This builds on the success of the companies’ existing collaboration and continues to combine both companies’ deep biology and technology expertise. The collaboration will leverage Regeneron’s proprietary antibody-targeted adeno-associated virus (AAV) vectors and delivery systems and Intellia’s proprietary Nme2 CRISPR/Cas9 (Nme2Cas9) systems adapted for viral vector delivery and designed to precisely modify a target gene.

“To date, the widespread use of genetic medicines has generally been limited by the inability to deliver a genetic payload to cells of interest in the body beyond the liver. This expansion of our longstanding and productive collaboration with Intellia is taking advantage of new technology and innovations to unlock these opportunities,” said Aris Baras, M.D., Senior Vice President and Co-Head of Regeneron Genetic Medicines.

“Regeneron has invented and preclinically validated a proprietary antibody-directed AAV approach that builds on our decades of experience in antibodies and newly developed AAV capsid engineering technologies to deliver innovative payloads across many targeted tissue types and disease settings. We’re excited to put this approach to the test in combination with Intellia’s industry-leading gene editing systems, in hopes of generating important new medicines for people with serious neurological and muscular diseases,” said Christos Kyratsous, Ph.D., Senior Vice President, Research, and Co-Head of Regeneron Genetic Medicines.

 

Page 1 of 5    intelliatx.com

“We are excited to expand our successful collaboration with Regeneron to now accelerate the development of CRISPR-based therapies outside of the liver for the treatment of neurological and muscular diseases with significant unmet need,” said Intellia President and Chief Executive Officer John Leonard, M.D. “At Intellia, we are continuously innovating our editing and delivery solutions to realize the full potential of CRISPR gene editing as a new therapeutic modality. This collaboration is representative of our long-standing belief that the most groundbreaking solutions will come from selecting the best tools for each individual application, all of which are enabled by our industry-leading genome editing toolbox.”

Under the terms of the expanded agreement, the companies will initially research two in vivo non-liver targets. Intellia will lead the design of the editing methodology and Regeneron will lead the design of the targeted viral vector delivery approach. Each company will have the opportunity to lead potential development and commercialization of product candidates for one target, and the company that is not leading development and commercialization will have the option to enter into a co-development and co-commercialization agreement for the target.

About Regeneron

Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, Regeneron’s unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron’s laboratories. Regeneron’s medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about Regeneron, please visit www.regeneron.com or follow Regeneron on LinkedIn.

About Intellia Therapeutics

Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine. Learn more at intelliatx.com. Follow us on X (formerly known as Twitter) @intelliatx.

 

Page 2 of 5    intelliatx.com

Regeneron Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, such as the research programs with Intellia Therapeutics, Inc. to develop in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases discussed in this press release; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), as well as Regeneron’s collaboration with Intellia discussed in this press release, to be cancelled or terminated; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees (including those conducted as part of the collaboration with Intellia discussed in this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the potential of utilizing for therapeutic purposes Regeneron’s novel adeno-associated virus (AAV) vectors and delivery systems and Intellia’s proprietary Nme2 CRISPR/Cas9 (Nme2Cas9) systems adapted for viral vector delivery as discussed in this press release; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary, including those discussed or referenced in this press release) on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron’s Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on Regeneron’s business; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection and REGEN-COV® (casirivimab and imdevimab)), other litigation and other proceedings and government investigations relating to the Company and/or its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2022 and its Form 10-Q for the quarterly period ended June 30, 2023. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

 

Page 3 of 5    intelliatx.com

Intellia Forward-Looking Statements

This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations regarding its: research and development of a proprietary Nme2Cas9 system adapted for viral vector delivery and the combination of that system with Regeneron Pharmaceuticals, Inc.’s (“Regeneron”) proprietary antibody-targeted adeno-associated virus vectors and delivery systems to develop product candidates for neurological and muscular diseases, including development and design of editing methodologies for such product candidates; ability to accelerate the development of CRISPR-based therapies outside of the liver for the treatment of neurological and muscular diseases with significant unmet need; advancement and expansion of its CRISPR/Cas9 technology to develop human therapeutic products, including its ability to continuously innovate its editing and delivery solutions to realize the full potential of CRISPR gene editing as a new therapeutic modality and to enable groundbreaking solutions with its industry-leading genome editing toolbox; ability to lead the potential development and commercialization of product candidates for in vivo non-liver targets; ability to maintain and expand its intellectual property portfolio related to CRISPR/Cas9 technology; and ability to optimize the impact of its collaborations on its development programs, including but not limited to its collaboration with Regeneron.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including Regeneron and its other licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to the research, development and commercialization of product candidates for neurological and muscular diseases, including product candidates that combine Intellia’s proprietary Nme2Cas9 system with Regeneron’s proprietary antibody-targeted adeno-associated virus vectors and delivery systems; the risk that any one or more of Intellia’s product candidates, or product candidates it develops with Regeneron, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and the risk that Intellia’s collaboration Regeneron will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K or quarterly report of Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.

 

Page 4 of 5    intelliatx.com

Regeneron Contacts:

Investors:

Vesna Tosic

+1-914-847-5443

vesna.tosic@regeneron.com

Media:

Ella Campbell

+1-914-847-7017

ella.campbell@regeneron.com

Intellia Contacts:

Investors:

Ian Karp

Senior Vice President, Investor Relations and Corporate Communications

+1-857-449-4175

ian.karp@intelliatx.com

Lina Li

Senior Director, Investor Relations and Corporate Communications

+1-857-706-1612

lina.li@intelliatx.com

Media:

Matt Crenson

Ten Bridge Communications

+1-917-640-7930

media@intelliatx.com

mcrenson@tenbridgecommunications.com

# # #

 

Page 5 of 5    intelliatx.com
 EX-101.SCH 3 ntla-20231003.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 ntla-20231003_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 ntla-20231003_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g556975g00a01.jpg GRAPHIC begin 644 g556975g00a01.jpg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g556975g1003023457499.jpg GRAPHIC begin 644 g556975g1003023457499.jpg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g556975g1003023457823.jpg GRAPHIC begin 644 g556975g1003023457823.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Oct. 03, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001652130
Document Type 8-K
Document Period End Date Oct. 03, 2023
Entity Registrant Name INTELLIA THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-37766
Entity Tax Identification Number 36-4785571
Entity Address, Address Line One 40 Erie Street
Entity Address, Address Line Two Suite 130
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code (857)
Local Phone Number 285-6200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol NTLA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 10 d556975d8k_htm.xml IDEA: XBRL DOCUMENT 0001652130 2023-10-03 2023-10-03 false 0001652130 8-K 2023-10-03 INTELLIA THERAPEUTICS, INC. DE 001-37766 36-4785571 40 Erie Street Suite 130 Cambridge MA 02139 (857) 285-6200 false false false false Common Stock, par value $0.0001 per share NTLA NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

$0 >&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !M.D-799!YDAD! #/ P M$P @ '#$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 .."0 ) #X" -% ! end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d556975d8k.htm ntla-20231003.xsd ntla-20231003_lab.xml ntla-20231003_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d556975d8k.htm": { "nsprefix": "ntla", "nsuri": "http://intelliatx.com/20231003", "dts": { "inline": { "local": [ "d556975d8k.htm" ] }, "schema": { "local": [ "ntla-20231003.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] }, "labelLink": { "local": [ "ntla-20231003_lab.xml" ] }, "presentationLink": { "local": [ "ntla-20231003_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "report": { "R1": { "role": "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-10-03_to_2023-10-03", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d556975d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-10-03_to_2023-10-03", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d556975d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://intelliatx.com//20231003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001193125-23-249487-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-249487-xbrl.zip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